刘辉;于晓艳;孙波;李相军;任立群;李才;邹颖刚;李佳;

• 1:吉林大学药学院实验药理与毒理教研室
• 2:吉林大学第二临床医院

摘要(Abstract)：

目的探讨晚期糖基化终末产物(Advanced glycosylation end products,AGEs)对大鼠肾小管上皮细胞NRK-52E组织型转谷氨酰胺酶(Tissue transglutanunase,tTG)mRNA表达及其对细胞外基质(Extracellular matrix,ECM)降解的影响。方法体外培养NRK-52E细胞,分别用体外合成的不同浓度的糖化牛血清白蛋白(AGE-BSA)及未经糖化的牛血清白蛋白(BSA)处理48h,ELISA法检测细胞培养上清中纤维连接蛋白(Fibronectin,FN)和Ⅳ型胶原蛋白(TypeⅣcollagen,ColⅣ)含量,RT-PCR检测细胞tTG mRNA的表达。结果与BSA组比较,50～200mg/LAGE-BSA组细胞上清中FN含量明显增加(P<0.01),25～100mg/L AGE-BSA组细胞上清中ColⅣ含量明显增加(P<0.05);AGE-BSA(50～400mg/L)可不同程度地刺激细胞tTG mRNA表达的增加(P<0.05);tTG mRNA表达增加与FN、ColⅣ分泌增多呈正相关(r值分别为0.911和0.872)。结论 AGEs能诱导大鼠近端肾小管上皮细胞tTG mRNA的表达,引起ECM主要成分FN和ColⅣ含量增加,提示tTG可能在AGEs引起的ECM积聚过程中,起到抑制ECM蛋白降解的作用,进而参与糖尿病肾病的病理过程。

关键词(KeyWords)： 糖基化终末产物,高级;组织型转谷氨酰胺酶;糖尿病肾病;细胞外基质

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金资助课题(30800423)

作者(Authors): 刘辉;于晓艳;孙波;李相军;任立群;李才;邹颖刚;李佳;

DOI: 10.13200/j.cjb.2010.06.14.liuh.025

参考文献(References)：

• [1]Vlassara H,Bucala R,Striker L.Pathogenic effects of advanced glycosylation:biochemical,biologic and clinical implications for diabetes and aging[J].Lab Invest,1994,70(2):138-151.
• [2]Zhou G,Li C,Cai L.Advanced glycation end-products induce con-nective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway[J].Am J Pathol,2004,165(6):2033-2043.
• [3]Daroux M,Prévost G,Maillard-Lefebvre H,et al.Advanced glyca-tion end-products:implications for diabetic and non-diabetic nephropathies[J].Diabetes Metab,2010,36(1):1-10.
• [4]Soulis T,Cooper ME,Sastra S,et al.Relative contributions of ad-vanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats[J].Dia-betologia,1997,40(10):1141-1151.
• [5]Aeschlimann D,Thomazy V.Protein crosslinking in assembly and remodelling of extracellular matrices:the role of transglutaminases[J].Connect Tissue Res,2000,41(1):1-27.
• [6]Thomas MC,Forbes JM,Cooper ME.Advanced glycation end prod-ucts in diabetic nephropathy[J].Am J Ther,2005,12(6):562-572.
• [7]Poon PY,Szeto CC,Chow KM,et al.Relation between polymor-phisms of receptor for advanced glycation end products(RAGE)and cardiovascular diseases in Chinese patients with diabeticnephropathy[J].Clin Nephrol,2010,73(1):44-50.
• [8]Oldfield MD,Bach LA,Forbes JM,et al.Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products(RAGE)[J].J Clin Invest,2001,108(12):1853-1863.
• [9]Yu X,Li C,Li X,et al.Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1[J].Toxicol Sci,2007,96(2):346-356.
• [10]Johnson TS,El-Koraie AF,Skill NJ,et al.Tissue transglutami-nase and the progression of human renal scarring[J].J Am Soc Nephrol,2003,14(8):2052-2062.
• [11]Skill NJ,Griffin M,El Nahas AM,et al.Increases in renal ep-silon(-gamma-glutamyl)-lysine crosslinks result from compart-ment-specific changes in tissue transglutaminase in early experi-mental diabetic nephropathy:pathologic implications[J].Lab In-vest,2001,81(5):705-716.
• [12]Chen D,Huang HC,Yu L.Expression and implication of tissue transglitaminase and connective tissue growth factor at fibrotic tubulointerstitium in kidneys from UUO rats[J].Beijing Da Xue Xue Bao,2005,37(2):143-146.
• [13]Zeisberg M,Khurana M,Rao VH,et al.Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease[J].PLoS Med,2006,3(4):e100.
• [14]Nardacci R,Lo Iacono O,Ciccosanti F,et al.Transglutaminase type II plays a protective role in hepatic injury[J].Am J Pathol,2003,162(4):1293-1303.